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Abstract
Purpose: Right ventricular (RV) outflow tract obstruction (RVOTO) was demonstrated to be protective against RV 
dilatation in patients with repaired tetralogy of Fallot and chronic pulmonary regurgitation (PR). We hypothesised 
that the presence of additional haemodynamic abnormalities (more than mild tricuspid regurgitation, residual ven-
tricular septal defect) reduces this protective association. Accordingly, we aimed to assess the impact of PR on RV 
size and function in this population.
Material and methods: Consecutive patients with additional haemodynamic abnormalities after tetralogy of Fallot (TOF) 
repair, who had undergone cardiovascular magnetic resonance, were included.
Results: Out of 90 patients studied, 18 individuals (mean age 32.5 ± 10.7 years, 72.2% males) met the inclusion cri-
teria. There were no differences in RV volumes and ejection fraction between patients with and without RVOTO. 
Neither PR fraction (PRF) nor PR volume (PRV) correlated with RV end-diastolic volume (r = 0.36; p = 0.15 and  
r = 0.37; p = 0.14, respectively, for PRF and PRV) or RV end-systolic volume (r = 0.2; p = 0.42 and r = 0.19; p = 0.45, 
respectively, for PRF and PRV). Similarly, no significant correlations were observed between PRF or PRV and RV 
ejection fraction (r = –0.04; p = 0.87 and r = –0.03; p = 0.9, respectively).
Conclusions: Additional haemodynamic abnormalities are associated with the abolition of the protective effect of 
RVOTO on RV size. There was no significant relationship between measures of PR and RV volumes in patients after 
TOF repair with concomitant haemodynamic abnormalities. These abnormalities acted as confounding factors in 
the assessment of the impact of pulmonary regurgitation on RV size and function. 
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Introduction
Pulmonary regurgitation (PR) is a common problem in 
patients with repaired tetralogy of Fallot (TOF) [1-6]. PR 
has been shown to have a detrimental impact on right ven-
tricular (RV) size and function in various patient popula-
tions [5,7-14]. Additionally, ventricular performance and 
size can be compromised by other pathologies such as 
valvular insufficiency at a valve other than the pulmonary 
valve (e.g. tricuspid regurgitation) and/or residual ven-
tricular septal defect (VSD) [1-3].
Cardiovascular magnetic resonance (CMR) is con-
sidered the diagnostic modality of choice for evaluating 
the right ventricle [1-4,15]. Unlike echocardiography, it 
enables the complex RV anatomy and function to be as-
sessed accurately and reproducibly [1-5,15,16].
Mateusz Śpiewak, Joanna Petryka-Mazurkiewicz, Łukasz Mazurkiewicz et al.  
e608 © Pol J Radiol 2020; 85: e607-e612
Concomitant haemodynamic abnormalities (signifi-
cant tricuspid regurgitation, residual ventricular septal 
defect – VSD) are often observed in patients after repair 
of TOF [1-4,17-19]. To date, there have been no studies 
addressing the influence of PR on the right ventricle in 
patients with repaired TOF and additional haemody-
namic abnormalities. It has been demonstrated that right 
ventricular outflow tract (RVOT) obstruction (RVOTO) 
is a confounding (protective) factor in assessing how PR 
impacts RV size and function in patients with repaired 
TOF [20]. We hypothesised that a potential protective ef-
fect of RVOTO on RV size and performance is hampered 
in patients with additional haemodynamic abnormalities. 
Additionally, we aimed to assess the impact of PR on RV 
size and function in patients with repaired TOF and con-
comitant haemodynamic abnormalities. To evaluate these 
issues, we decided to perform the current study.
Material and methods
The study population included consecutive patients with 
repaired TOF repair, who had undergone a CMR study. 
Patients with more than mild tricuspid regurgitation (as 
assessed by echocardiography) and/or residual VSD were 
included. Exclusion criteria comprised the following: 
(1) poor quality of CMR images, (2) incomplete CMR 
study, (3) incomplete echocardiographic dataset, (4) no 
echocardiographic assessment performed within one year 
of CMR study, (5) extracardiac shunt, (6) more than mild 
regurgitation at a valve other than pulmonic or tricuspid 
valve, and (7) absence of additional haemodynamic ab-
normalities. 
All patients underwent transthoracic echocardiogra-
phy with commercially available systems. Peak instanta-
neous RVOT gradient was calculated with the use of the 
Bernoulli equation on the basis of the maximal velocity 
across RVOT. Peak gradient greater or equal to 30 mm Hg 
was considered significant [1]. All patients were screened 
for the presence of residual VSD and/or significant (at 
least moderate) regurgitation at a valve other than the 
pulmonary valve.
All CMR imaging studies were performed with a 1.5 T 
system (Avanto, Siemens, Erlangen, Germany). The volu-
metric analysis of the right and left ventricles was per-
formed on the basis of short axis balanced steady-state 
free precession breath-hold images with the use of dedi-
cated software (Mass 6.2.1, Medis, Leiden, Netherlands). 
Epicardial and endocardial borders were outlined man-
ually at end-systole and end-diastole. On the basis of 
these data, the following parameters were calculated: RV 
end-diastolic volume (RVEDV), RV end-systolic volume 
(RVESV), RV stroke volume (RVSV), RV ejection frac-
tion (RVEF) and RV mass (RVM), left ventricular (LV) 
end-diastolic volume (LVEDV), LV end-systolic volume 
(LVESV), LV stroke volume (LVSV), LV ejection frac-
tion (LVEF), and LV mass (LVM). All parameters were 
indexed for body surface area (BSA). The trabeculae and 
papillary muscles were included in blood pool. Imag-
ing parameters were as follows: effective repetition time 
33 to 54 ms, echo time 1.2 ms, flip angle 64° to 79°, slice 
thickness 8 mm, gap 1.6 mm, in plane image resolution 
1.6 × 1.6 mm to 1.8 × 1.8 mm, and temporal resolution 
25 to 40 phases per cardiac cycle. A flow sensitive gradient 
echo sequence acquired during free breathing (effective 
repetition time 30 to 47 ms, echo time 2 ms, flip angle 30°, 
slice thickness 5 mm) and dedicated software (Argus, Sie-
mens, Erlangen, Germany) were used for the calculation 
of pulmonary forward and backward flows. The imaging 
plane was located at the midpoint of the main pulmonary 
artery or conduit and prescribed perpendicular to the ves-
sel by the double oblique technique, PR fraction (PRF) 
was calculated as percentage of backward flow over for-
ward flow, and PR volume (PRV) as a total reverse flow 
indexed for BSA. PRF ≥ 20% was considered significant 
PR [13,14]. All CMR studies were screened for the pres-
ence of extracardiac shunt (e.g. major aortopulmonary 
collateral arteries).
All variables were tested for normal distribution with 
the use of the Kolmogorov-Smirnov test. Normally dis-
tributed variables were expressed as mean ± SD. Correla-
tions were expressed with the Pearson rank correlation 
coefficients. Comparisons between continuous variables 
with normal distribution were performed with the use 
of the t-test for unpaired samples. A probability value of 
p < 0.05 was considered statistically significant. All statis-
tical analyses were conducted with the use of Medcalc sta-
tistical software, version 10.0.2.0 (MedCalc, Mariakerke, 
Belgium).
The local Research Committee approved of the retro-
spective review of medical records and computer data-
bases. Each patient gave their informed consent for par-
ticipation in the CMR study.
Results 
Out of 90 patients with repaired TOF, who had undergone 
CMR, 18 individuals met the inclusion criteria. Patients 
with poor quality of CMR images precluding analysis 
(n = 3), incomplete CMR study (n = 1), incomplete echo-
cardiographic dataset (n = 2), no echocardiographic as-
sessment performed within one year of CMR study (n = 3), 
extracardiac shunt (n = 1), more than mild regurgitation at 
a valve other than the pulmonic or tricuspid valve (n = 1), 
and those with no additional haemodynamic abnormali-
ties (n = 61) were excluded from the analysis. The remain-
ing patients (n = 18) formed the study population.
Twelve patients (66.7%) underwent CMR and echo 
studies on the same day. In four patients (22.2%), an echo 
study was performed within 30 days of a CMR study. 
The clinical characteristics of the study population are 
summarised in Table 1. Table 2 presents the CMR and 
echocardiographic characteristics. 
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In nine patients (50%) the peak gradient across RVOT 
was ≥ 30 mm Hg. There were no differences between pa-
tients with and without RVOTO in RV size and function 
either in the whole group (RVEDV: 158.8 ± 62.5 ml/m2 vs. 
160.8 ± 35.2 ml/m2; p = 0.92, RVESV: 87.7 ± 56.5 ml/m2 
vs. 84.1 ± 29.0 ml/m2; p = 0.87 and RVEF: 47.8 ± 11.4% 
vs. 48.4 ± 11.5%; p = 0.9) or in patients with significant PR 
(RVEDV [p = 0.94]; RVESV [p = 0.65]; RVEF [p = 0.36]). 
Neither PRF nor PRV correlated with RVEDV or 
RVESV (Table 3). Similarly, no significant correlations 
were observed between PRF or PRV and RVEF (Table 3). 
In a subgroup of patients with significant PR (n = 13), 
the relationship between the degree of PR (measured as 
PRF or PRV) and RV size and function was even poorer 
(Table 3).
There were no correlations between peak RVOT gra-
dient and RVEDV, RVESV, or RVEF (Table 3). 
Discussion
It has been previously presented that RVOTO acts as a pro-
tective factor in the assessment of PR impact on RV size 
and function in patients after TOF repair [20]. However, in 
our study comprising a population with additional haemo-
dynamic abnormalities, we found no differences in RV size 
and function between patients with and without RVOTO. 
Previous studies in various patient populations after TOF 
repair demonstrated a linear relationship between PR and 
RV volumes [11-13,21]. These studies included both un-
selected patient populations as well as patients without 
tricuspid regurgitation and/or residual VSD. In a selected 
Table 1. Baseline characteristics of the study population
Parameter Total population
N = 18
Males, n (%) 13 (72.2)
Age at CMR study, years 32.5 ± 10.7
Age at TOF repair, years 12.5 ± 12.4
Time from TOF repair, years 20.0 ± 6.3
Type of TOF repair, n (%)
Patch 13 (72.2)
Conduit 4 (22.2)
Details unknown 1 (5.6)
Age at first palliation, years 2.9 ± 3.0
Time from first palliation to TOF repair, years 7.3 ± 9.9
Palliative procedure in the history, n (%) 6 (33.3)
Blalock-Taussig, n (%) 5 (27.7)
Waterston, n (%) 1 (5.6)
Residual VSD, n (%) 14 (77.8)†
Significant tricuspid regurgitation, n (%) 6 (33.3)†
CMR – cardiovascular magnetic resonance, IQR – interquartile range, TOF – tetralogy of Fallot, 
VSD – ventricular septal defect 
†In 2 patients both abnormalities were observed
Table 2. Cardiovascular magnetic resonance and echocardiographic charac-
teristics of the study population 
RVEDV (ml/m2) 159.6 ± 49.2
RVESV (ml/m2) 85.9 ± 43.6
RVSV (ml/m2) 76.2 ± 17.4
RVEF (%) 48.1 ± 11.1
PRF (%) 27.4 ± 15.1
PRV (ml/m2) 20.9 ± 12.1
peak RVOT gradient (mm Hg) 25.2 ±20.2
RVM (g/m2) 32.8 ± 12.5
LVEDV (ml/m2) 89.9 ± 15.8
LVESV (ml/m2) 40.9 ± 13.2
LVSV (ml/m2) 48.9 ± 8.4
LVEF (%) 56.6 ± 8.3
LVM (g/m2) 59.2 ± 13.6
All parameters but for peak RVOT gradient were derived from CMR measurements.
LVEDV – left ventricular end-diastolic volume, LVEF – left ventricular ejection fraction, 
LVESV – left ventricular end-systolic volume, LVM – left ventricular mass, LVSV – left ventricu-
lar stroke volume, RVEDV – right ventricular end-diastolic volume, RVEF – right ventricular 
ejection fraction, RVESV – right ventricular end-systolic volume, RVM – right ventricular mass, 
RVSV – right ventricular stroke volume, PRF – pulmonary regurgitation fraction, PRV – pulmo-
nary regurgitation volume, RVOT – right ventricular outflow tract
Table 3. Correlations between pulmonary regurgitation fraction, pulmonary regurgitation volume, peak right ventricular outflow tract gradient vs. right 
ventricular volumes and right ventricular ejection fraction
Parameter PRF PRV Peak RVOT gradient
All patients
(n = 18)
Significant PR
(n = 13)
All patients
(n = 18)
Significant PR
(n = 13)
All patients
(n = 18)
Significant PR
(n = 13)
RVEDV r = 0.36
p = 0.15
r = –0.06
p =0.84
r = 0.37
p = 0.14
r = 0.003
p = 0.99
r = –0.14
p = 0.57
r = –0.13
p = 0.67
RVESV r = 0.20
p = 0.42
r = –0.06
p =0.85
r = 0.19
p = 0.45
r = –0.10
p = 0.75
r = –0.08
p = 0.74
r = 0.03
p = 0.93
RVEF r = –0.04
p = 0.87
r = –0.21
p =0.49
r = –0.03
p = 0.90
r = –0.02
p = 0.94
r = 0.19
p = 0.46
r = –0.02
p = 0.95
RVEDV – right ventricular end-diastolic volume, RVEF – right ventricular ejection fraction, RVESV – right ventricular end-systolic volume, RVM – right ventricular mass, RVSV – right ventricular 
stroke volume, PRF – pulmonary regurgitation fraction, PRV – pulmonary regurgitation volume, RVOT – right ventricular outflow tract
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patient population with additional haemo dynamic abnor-
malities, we have proven that neither measures of PR nor 
peak RVOT gradient correlated with RV size and RVEF. 
Therefore, other haemodynamic pathologies such as tri-
cuspid regurgitation or residual VSD have to be considered 
when the impact of PR on RV is assessed. 
The causes of lack of relationship between PR and 
RV size and function are multifactorial. First, in 33.3% 
of patients more than mild regurgitation at a valve other 
than the pulmonary valve, mainly ≥ moderate tricuspid 
regurgitation (n = 6) was observed, which causes extra 
volume burden on the RV and leads to RV dilatation. Sec-
ondly, although isolated VSD does not cause RV enlarge-
ment, guidelines on congenital heart disease indicate that 
in patients with repaired TOF a combination of residual 
VSD, RVOTO, and/or PR leads to progressive RV dilata-
tion and impaired RV systolic function [1,3]. Finally, the 
mean RVEDV in the study group was close to 170 ml/m2, 
which is considered as severe RV dilatation [21,22]. It can 
be speculated that in patients with severe RV enlargement 
the volume overload of PR may not cause a relationship 
between PR and RVEDV or RVESV.
The findings of our study may be clinically relevant 
when a decision is made about performing pulmonary 
valve replacement. One could expect that the bigger PR 
is, the larger RV size (volume) is observed. However, as 
presented in our study, this notion did not hold true for 
the population studied, because no correlation between 
PR severity and RVEDV was noted. Consequently, the 
decision about performing pulmonary valve replacement 
may be influenced by this false opinion.
We have no data concerning the onset of additional 
haemodynamic abnormalities relative to the TOF repair 
or relative to the CMR examination. It is, therefore, un-
known whether those pathologies were present in all pa-
tients since the time of the TOF repair. This needs to be 
elucidated in further studies. 
We used two different software solutions (Mass by Me-
dis and Argus by Siemens), as available in our centre, for 
quantitative analyses, which can be considered as a limita-
tion. However, this approach is rather common in CMR 
studies because different software is used for ventricular 
size and function analysis than for flow estimation.
Although CMR estimates of RVOT gradient pressure 
show better (versus echocardiography) correlation with 
the findings of cardiac catheterisation, according to guide-
lines for the management of congenital heart diseases we 
decided to use echocardiography to calculate the peak 
RVOT gradient [1-4,24]. 
This is a preliminary report, and the number of pa-
tients is relatively small and might seem not large enough 
to make reasonable conclusions. However, CMR is char-
acterised as the most reproducible non-invasive method 
of assessing ventricular size and function. This in turn en-
abled us to limit the number of patients needed to detect 
a statistically significant difference [25,26]. Nevertheless, 
Figure 2. Representative echocardiography image in a patient with residual 
ventricular septal defect (VSD). Parasternal colour Doppler short-axis view 
demonstrating VSD of a diameter of 8 mm
Figure 1. Representative cardiac magnetic resonance images in a patient with significant tricuspid regurgitation and its consequences. A) Steady-state 
free precession single shot axial image demonstrating severely dilated right atrium (white asterisk), dilated vena cava inferior (black asterisk), and dilated 
coronary sinus (yellow asterisk). B) Steady-state free precession 4-chamber view cine image demonstrating severely dilated right atrium
A B
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because of the small patient number and the heterogene-
ity of concomitant lesions, the results of the current study 
should be confirmed or refuted through larger trials. 
Computed tomography is ideally suited to the de-
tection of various other congenital abnormalities of the 
cardiovascular system in patients with TOF [27]. There-
fore, it should be elucidated whether incorporation of this 
technique provides additional information to interpret the 
findings of our study. Further studies aimed at ascertain-
ing how to incorporate these abnormalities into clinical 
decision making are needed.
Conclusions
The potential protective effect of RVOTO on RV size and 
performance may be hampered by other haemodynamic 
abnormalities. There are no significant relations between 
measures of PR and RV volumes in patients after TOF 
repair with concomitant haemodynamic abnormalities. 
These abnormalities act as confounding factors in assess-
ing how PR impacts RV size and function. 
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